CoronaCheck™
A rapid, reliable, non-invasive test for corona
virus in exhaled breath
Cambridge, England, 4 January 2021 – Exhalation Technology Updates on Groundbreaking Clinical Trial for CoronaCheck
New clinical data on the CoronaCheck Covid-19 exhaled breath test shows absolute specificity and sensitivity in a test taking under 5 minutes at under $10.
To read the full press release - Exhalation Technology (ETL) Announces New Clinical Trial for CoronaCheck™ – A Rapid Covid-19 Test for Exhaled Breath
Coronavirus threatens every part of the World. It’s a global problem calling for global solutions.
The rapid spread in coronavirus leads to a need for reliable Point of Care (PoC) tools enabling rapid screening for the virus.
Current coronavirus testing doesn’t offer the desired reliability, typically resulting in too many false negatives. People infected with coronavirus are not detected by the system and return to their normal lives, believing they are not infected, yet spreading the virus.
At the same time, existing coronavirus testing methods are not developed for PoC use. They typically offer RNA/DNA tests on nasal or mouth swabs requiring laboratory equipment for analysis and manual handling of the sample from each tests subject.
Coronavirus spreads via small droplets in breath, aerosols, and scientific evidence exists to support the accurate detection of virus by Exhaled Breath Condensate (EBC.)
Thus, testing for the virus in EBC seems to be an obvious opportunity to pursue.
We are proud to announce that our project is funded by Innovate UK, the UK’s innovation agency.
Our Solution
The CoronaCheck™
A game changing PoC screening device to be used at the frontline in the fight against coronavirus.
CoronaCheck™ is a development of an existing technology, the Inflammacheck®, which is the only device in the market designed to collect EBC and tests for compounds directly therein at PoC.
We, at Exhalation Medical Technology, have been granted a license to explore this opportunity.
Technology platform
The Inflammacheck®
The Inflammacheck®, proprietary technology of Exhalation Technology, is a handheld, non-invasive, PoC diagnostic device. In its original form it detects hydrogen peroxide, H2O2, in EBC, a well-documented biomarker for inflammatory conditions in the airways system. The full test cycle, including sample collection and test assay, typically takes place in 5 minutes ,following a fully automated procedure.
The Inflammacheck® is CE marked and is registered with the MHRA for sales and use in the UK as well as in the EU.
Sensor technology
The Inflammacheck® platform will be repurposed to enable screening for coronavirus following a similar fully automatic procedure.
A highly specific sensor platform will be developed by immobilising a receptor to which coronavirus has a very strong affinity. Thus, coronavirus is expected to bind to the sensor, thereby producing a measurable signal.
The device will be modified to make it better suited in testing for a highly infectious virus. The sensor is fully integrated with the breath collection system in a fully enclosed, disposable unit to mitigate the risk of cross-infections between users.
